$9.59
1.80% yesterday
Nasdaq, Dec 24, 09:54 pm CET
ISIN
US45826J1051
Symbol
NTLA

Intellia Therapeutics, Inc. Stock price

$9.59
+1.24 14.85% 1M
+0.02 0.21% 6M
-2.07 17.75% YTD
-2.46 20.41% 1Y
-25.39 72.58% 3Y
-52.55 84.57% 5Y
-12.51 56.61% 10Y
-12.51 56.61% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.17 1.80%
ISIN
US45826J1051
Symbol
NTLA
Industry

New AI Insights on Intellia Therapeutics, Inc. Insights AI Insights on Intellia Therapeutics, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$599.8m
Net debt
positive
Cash
$511.0m
Shares outstanding
115.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
19.3 | 18.8
EV/Sales
10.4 | 10.2
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
73.2%
Return on Equity
-59.5%
ROCE
-57.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$57.5m | $59.0m
EBITDA
$-468.8m | $-448.7m
EBIT
$-478.7m | $-460.3m
Net Income
$-445.8m | $-468.0m
Free Cash Flow
$-412.6m
Growth (TTM | estimate)
Revenue
-29.2% | 2.0%
EBITDA
48.1% | 14.4%
EBIT
47.6% | 13.8%
Net Income
48.8% | 9.8%
Free Cash Flow
-13.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-814.9% | -760.5%
EBIT
-832.2%
Net
-774.9% | -793.1%
Free Cash Flow
-717.3%
More
EPS
$-4.0
FCF per Share
$-3.6
Short interest
43.2%
Employees
403
Rev per Employee
$140.0k
Show more

Is Intellia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Intellia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Intellia Therapeutics, Inc. forecast:

17x Buy
55%
12x Hold
39%
2x Sell
6%

Analyst Opinions

31 Analysts have issued a Intellia Therapeutics, Inc. forecast:

Buy
55%
Hold
39%
Sell
6%

Financial data from Intellia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
58 58
29% 29%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 119 119
43% 43%
207%
- Research and Development Expense 417 417
47% 47%
725%
-469 -469
48% 48%
-815%
- Depreciation and Amortization 9.95 9.95
2% 2%
17%
EBIT (Operating Income) EBIT -479 -479
48% 48%
-832%
Net Profit -446 -446
49% 49%
-775%

In millions USD.

Don't miss a Thing! We will send you all news about Intellia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Intellia Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
20 days ago
CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2025, it awarded inducement grants to three new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.
Neutral
Seeking Alpha
about one month ago
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Negative
The Motley Fool
about one month ago
Intellia Therapeutics and Sarepta Therapeutics have hit serious setbacks potentially linked to their treatments. Both biotechs have lost market value as a result, but both still seem too risky to consider investing in right now.
More Intellia Therapeutics, Inc. News

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO John Leonard
Employees 403
Founded 2014
Website www.intelliatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today